The present invention relates to peptides capable of forming a gel and to their use in tissue engineering and bioprinting. The present invention furthermore relates to a gel comprising a peptide in accordance with the present invention, to a method of preparing such gel and to the use of such gel. In one embodiment, such gel is a hydrogel. The present invention furthermore relates to a wound dressing or wound healing agent comprising a gel according to the present invention and to a surgical implant or stent comprising a peptide scaffold formed by a gel according to the present invention. Moreover, the present invention also relates to a pharmaceutical and/or cosmetic composition, to a biomedical device or an electronic device comprising the peptide according to the present invention.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NHCH(CH.sub.2SO.sub.3H)COOH or Arg-Gly-NHCH(CH.sub.2SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

A degradable iron-based alloy stent comprises an iron-based alloy substrate and a degradable polymer in contact with the surface of the substrate. The weight-average molecular weight of the degradable polymer is in the range of [1, 100]*10.sup.4, and the polydispersity index of the degradable polymer is in the range of (1.0, 50]. The degradable polymer is selected from a degradable polyamino acid that can generate an acidic amino acid after degradation; or a mixture of the degradable polyamino acid and a degradable polyester, or a copolymer of monomers of the two; or a mixture of the degradable polyamino acid and a degradable polymer that does not generate acidic products after degradation, or a copolymer of the monomers of the two; or a mixture of the degradable polyamino acid, the degradable polyester and the degradable polymer that does not generate acidic products after degradation, or a copolymer of monomers of the three, or a mixture of a copolymer of monomers of any two of the three with the remaining one. The numerical ranges are in conformity with mathematical knowledge, i.e. [a, b] means being greater than or equal to a and being less than or equal to b; (a, b] means being greater than a and less than or equal to b; [a, b) means being greater than or equal to a, less than b, a redundant description will not be provided for the similarity text below.

An orthodontic adhesive includes components capable of allowing easy debonding of an orthodontic device from a patient's tooth. The adhesive includes an engineered marine mussel protein. The adhesive may include at least one photocleavable moiety. The adhesive is applied in one or more individual layers. One of the components of the adhesive is capable of binding to a tooth and the other component may be capable of binding to an orthodontic device. A method of adhering an orthodontic device to a tooth includes applying a layer of an orthodontic adhesive to either the tooth or the orthodontic device or the tooth and the orthodontic device and affixing the orthodontic device to the tooth with the orthodontic adhesive situated between the tooth and the orthodontic device. The engineered marine mussel protein includes one or more catechol moieties or one or more derivatives of a catechol moiety.

The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NHCH(CH.sub.2SO.sub.3H)COOH or Arg-Gly-NHCH(CH.sub.2SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to .sub.5.sub.1-Integrin, .sub.v.sub.3-Integrin and .sub.v.sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

A system for treating a patient comprises a delivery device and injectate. The delivery device comprises an elongate shaft with a distal portion and at least one delivery element positioned on the elongate shaft distal portion. The delivery device is constructed and arranged to deliver the injectate through the at least one delivery element and into tissue to create a therapeutic restriction in the gastrointestinal tract. Methods of creating a therapeutic restriction are also provided.

To reduce the risk of a ruptured suture after a surgery or the like, a medical apparatus includes a biodegradable sheet in which a plurality of through-holes are formed, a value of a ratio (D/P) of a hole diameter D to a pitch P of the through-hole is in a range of 0.25 or more and less than 40. Such a medical apparatus is useful as an adhesion promoting device for promoting adhesion of biological tissue.

Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NHCH(CH.sub.2SO.sub.3H)COOH or Arg-Gly-NHCH(CH.sub.2SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.